NCT02451982 2025-12-03
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT02845323 2025-07-15
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT02420938 2016-12-06
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00612664 2015-10-12
Phase II, 2nd Line Melanoma - RAND Monotherapy
Bristol-Myers Squibb
Phase 2 Completed